Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Grand View Research | PRODUCT CODE: 1376144

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1376144

Erectile Dysfunction Drugs Market Size, Share & Trends Analysis Report By Product (Viagra, Cialis, Zydena, Levitra, Stendra, Others), By Region (North America, Europe, APAC, Latin America, MEA), And Segment Forecasts, 2023 - 2030

PUBLISHED:
PAGES: 79 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Erectile Dysfunction Drugs Market Growth & Trends:

The global erectile dysfunction drugs market size is expected to reach USD 4.79 billion by 2030, according to a new study by Grand View Research, Inc.. The market is expected to expand at a CAGR of 8.8% from 2023 to 2030. The increasing prevalence of erectile dysfunction is expected to contribute to market growth. According to the European Association of Urology, the overall prevalence of ED was found to be around 52% in the European male population aged 40-70 years in 2020. In addition, according to the Boston University School of Medicine, approximately 22.0% of 40 years aged male population and 49.0% by age of 70 years are affected by erectile dysfunction. Thus, the increasing geriatric population is anticipated to increase the prevalence of ED over the forecast period and is expected to create lucrative growth opportunities in the market.

Eli Lilly and Company is supporting ED patients by offering medicine at low cost through Lilly Patient Support Program (LPSP). This program provides financial assistance to eligible ED uninsured patients in Canada who may require registration for this program. Thus, the presence of such supportive programs for a branded version of Cialis may increase the affordability of the lower-income patient population and also aid in generating increased revenue. Moreover, companies have undertaken initiatives such as collaboration and partnership for the manufacturing and commercialization of products in the overseas market. For instance, in January 2022, Petros Pharmaceuticals Inc. partnered with a global Contract Manufacturing Organization (CDMO) for the commercial production of Avanafil tablets. This partnership was formed with an aim to replace the existing agreement with Vivus Inc. and continue product supply.

Furthermore, according to the National Library of Medicine (2021), a phase 3 clinical trial was conducted by Sichuan Haisco Pharmaceutical Co., Ltd. to evaluate the safety and efficacy of Stendra in patients with ED in mainland China. The results of the clinical trial showed improvement in Chinese ED patients after administration of two doses of Stendra 100 mg & 200 mg. Such proven clinical effectiveness may strengthen Strenda's (Avanafil) position in the market. However, lack of awareness about erectile dysfunction, shame about treatment, false-positive beliefs, social stigma pertaining to the disease, and lack of discretion may restrain the market growth. As per the survey conducted by the European Association of Urology (EAU), only 18% of the Spanish population heard about ED treatment, whereas 68.0% of the population believes the treatment benefits.

Erectile Dysfunction Drugs Market Report Highlights:

  • By product, the viagra segment held the largest market share in 2022 due to the worldwide availability of Viagra and increased awareness about the product among ED patients
  • North America dominated the erectile dysfunction drugs market and accounted for a revenue share of 51.3% in 2022, due to the high burden of disease, strong healthcare infrastructure, and rapid approval of new products for treatment in the region.
  • Asia Pacific is expected to advance at the fastest CAGR of 10.2% during the forecast period. The growth of the region is attributable to the entry of new products into the region.
Show more
Product Code: 978-1-68038-604-2

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Regional scope
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Erectile Dysfunction Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Erectile Dysfunction Drugs Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's Five Forces
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Erectile Dysfunction Drugs Market: Product Estimates & Trend Analysis

  • 4.1. Erectile Dysfunction Drugs Market: Key Takeaways
  • 4.2. Erectile Dysfunction Drugs Market: Product Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Viagra
    • 4.3.1. Viagra market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Cialis
    • 4.4.1. Cialis market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Zydena
    • 4.5.1. Zydena market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Levitra
    • 4.6.1. Levitra market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Stendra
    • 4.7.1. Stendra market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Erectile Dysfunction Drugs Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Outlook
  • 5.2. Erectile Dysfunction Drugs Market by Region: Key Takeaways
  • 5.3. North America
    • 5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.2. U.S.
      • 5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.3. Canada
      • 5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4. Europe
    • 5.4.1. UK
      • 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.2. Germany
      • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.3. France
      • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.4. Italy
      • 5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.5. Spain
      • 5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.6. Sweden
      • 5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.7. Norway
      • 5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.8. Denmark
      • 5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.5. Asia Pacific
    • 5.5.1. Japan
      • 5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.2. China
      • 5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.3. India
      • 5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.4. Australia
      • 5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.5. Thailand
      • 5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.6. South Korea
      • 5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.6. Latin America
    • 5.6.1. Brazil
      • 5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.2. Mexico
      • 5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.3. Argentina
      • 5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.7. MEA
    • 5.7.1. Saudi Arabia
      • 5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.2. South Africa
      • 5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.3. UAE
      • 5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.4. Kuwait
      • 5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Market Participant Categorization
    • 6.2.1. Pfizer, Inc.
      • 6.2.1.1. Company overview
      • 6.2.1.2. Financial performance
      • 6.2.1.3. Product benchmarking
      • 6.2.1.4. Strategic initiatives
    • 6.2.2. Eli Lilly and Company
      • 6.2.2.1. Company overview
      • 6.2.2.2. Financial performance
      • 6.2.2.3. Product benchmarking
      • 6.2.2.4. Strategic initiatives
    • 6.2.3. Teva Pharmaceutical Industries Ltd.
      • 6.2.3.1. Company overview
      • 6.2.3.2. Financial performance
      • 6.2.3.3. Product benchmarking
      • 6.2.3.4. Strategic initiatives
    • 6.2.4. Sanofi
      • 6.2.4.1. Company overview
      • 6.2.4.2. Financial performance
      • 6.2.4.3. Product benchmarking
      • 6.2.4.4. Strategic initiatives
    • 6.2.5. Sun Pharmaceutical Industries Ltd.
      • 6.2.5.1. Company overview
      • 6.2.5.2. Financial performance
      • 6.2.5.3. Product benchmarking
      • 6.2.5.4. Strategic initiatives
    • 6.2.6. Bayer AG
      • 6.2.6.1. Company overview
      • 6.2.6.2. Financial performance
      • 6.2.6.3. Product benchmarking
      • 6.2.6.4. Strategic initiatives
    • 6.2.7. Petros Pharmaceuticals, Inc.
      • 6.2.7.1. Company overview
      • 6.2.7.2. Financial performance
      • 6.2.7.3. Product benchmarking
      • 6.2.7.4. Strategic initiatives
    • 6.2.8. VIVUS, Inc.
      • 6.2.8.1. Company overview
      • 6.2.8.2. Financial performance
      • 6.2.8.3. Product benchmarking
      • 6.2.8.4. Strategic initiatives
    • 6.2.9. Auxilium Pharmaceuticals
      • 6.2.9.1. Company overview
      • 6.2.9.2. Financial performance
      • 6.2.9.3. Product benchmarking
      • 6.2.9.4. Strategic initiatives
    • 6.2.10. Adamed
      • 6.2.10.1. Company overview
      • 6.2.10.2. Financial performance
      • 6.2.10.3. Product benchmarking
      • 6.2.10.4. Strategic initiatives
    • 6.2.11. Cipla Inc.
      • 6.2.11.1. Company overview
      • 6.2.11.2. Financial performance
      • 6.2.11.3. Product benchmarking
      • 6.2.11.4. Strategic initiatives
Show more
Product Code: 978-1-68038-604-2

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 3 North America erectile dysfunction drugs market, by region, 2018 - 2030 (USD Million)
  • Table 4 U.S. erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 5 Canada erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 6 Europe erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 7 Europe erectile dysfunction drugs market, by region, 2018 - 2030 (USD Million)
  • Table 8 Germany erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 9 UK erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 10 France erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 11 Italy erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 12 Spain erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 13 Sweden erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 14 Norway erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 15 Denmark erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 16 Asia Pacific erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific erectile dysfunction drugs market, by region, 2018 - 2030 (USD Million)
  • Table 18 Japan erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 19 China erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 20 India erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 21 Australia erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 22 Thailand erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 23 South Korea erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 24 Latin America erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 25 Latin America erectile dysfunction drugs market, by region, 2018 - 2030 (USD Million)
  • Table 26 Brazil erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 27 Mexico erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 28 Argentina erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 29 Middle East and Africa erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 30 Middle East and Africa erectile dysfunction drugs market, by region, 2018 - 2030 (USD Million)
  • Table 31 South Africa erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 32 Saudi Arabia erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 33 UAE erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 34 Kuwait erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Erectile dysfunction drugs: Market outlook
  • Fig. 9 Erectile dysfunction drugs: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Erectile dysfunction drugs market driver impact
  • Fig. 15 Erectile dysfunction drugs market restraint impact
  • Fig. 16 Erectile dysfunction drugs market strategic initiatives analysis
  • Fig. 17 Erectile dysfunction drugs market: Product movement analysis
  • Fig. 18 Erectile dysfunction drugs market: Product outlook and key takeaways
  • Fig. 19 Viagra market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 20 Cialis market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 21 Zydena market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 22 Levitra market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 23 Stendra market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 24 Others market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 25 Global erectile dysfunction drugs market: Regional movement analysis
  • Fig. 26 Global erectile dysfunction drugs market: Regional outlook and key takeaways
  • Fig. 27 North America market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 28 U.S. market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 29 Canada market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 30 Europe market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 31 UK market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 32 Germany market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 33 France market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 34 Italy market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 35 Spain market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 36 Sweden market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 37 Norway market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 38 Denmark market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 39 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 40 Japan market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 41 China market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 42 India market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 43 Australia market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 44 Thailand market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 45 South Korea market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 46 Latin America market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 47 Brazil market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 48 Mexico market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 49 Argentina market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 50 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 51 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 52 South Africa market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 53 UAE market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 54 Kuwait market estimates and forecasts, 2018 - 2030 (USD million)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!